HR
UTHR icon

Hardy Reed’s United Therapeutics UTHR Stock Holding History

Hardy Reed’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Buy
1,237
+5
+0.4% +$2.82K 0.04% 126
2026
Q1 		$731K Hold
1,232
– – 0.05% 113
2025
Q4 		$600K Buy
1,232
+15
+1% +$6.99K 0.04% 124
2025
Q3 		$510K Buy
1,217
+3
+0.2% +$1.01K 0.04% 139
2025
Q2 		$349K Hold
1,214
– – 0.03% 174
2025
Q1 		$374K Sell
1,214
-5
-0.4% -$1.71K 0.03% 156
2024
Q4 		$430K Buy
1,219
+5
+0.4% +$1.84K 0.04% 144
2024
Q3 		$435K Hold
1,214
– – 0.04% 148
2024
Q2 		$387K Buy
+1,214
New +$321K 0.04% 156

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Hardy Reed's UTHR Position: Q2 2026 in Review

Hardy Reed increased its United Therapeutics (UTHR) stake by 0.41% in Q2 2026, buying an estimated $2.82K and bringing the position to 1,237 shares worth $670K. The position accounts for 0.04% of the portfolio, ranked #126.

Hardy Reed first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $731K in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Hardy Reed held 1,237 shares of United Therapeutics worth $670K as of Q2 2026.
  • Hardy Reed bought 5 United Therapeutics shares in Q2 2026, an estimated $2.82K.
  • United Therapeutics made up 0.04% of Hardy Reed's portfolio in Q2 2026, its #126 holding.
  • Hardy Reed first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Hardy Reed's United Therapeutics position peaked at $731K in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Hardy Reed's 13F filing for Q2 2026, filed 3 Aug 2026.